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Abstract
Background: Protein aggregation plays important roles in several neurodegenerative disorders. For instance,
insoluble aggregates of phosphorylated tau and of Ab peptides are cornerstones in the pathology of Alzheimer’s
disease. Soluble protein aggregates are therefore potential diagnostic and prognostic biomarkers for their cognate
disorders. Detection of the aggregated species requires sensitive tools that efficiently discriminate them from
monomers of the same proteins. Here we have established a proximity ligation assay (PLA) for specific and
sensitive detection of Ab protofibrils via simultaneous recognition of three identical determinants present in the
aggregates. PLA is a versatile technology in which the requirement for multiple target recognitions is combined
with the ability to translate signals from detected target molecules to amplifiable DNA strands, providing very high
specificity and sensitivity.
Results: For specific detection of Ab protofibrils we have used a monoclonal antibody, mAb158, selective for Ab
protofibrils in a modified PLA, where the same monoclonal antibody was used for the three classes of affinity
reagents required in the assay. These reagents were used for detection of soluble Ab aggregates in solid-phase
reactions, allowing detection of just 0.1 pg/ml Ab protofibrils, and with a dynamic range greater than six orders of
magnitude. Compared to a sandwich ELISA setup of the same antibody the PLA increases the sensitivity of the Ab
protofibril detection by up to 25-fold. The assay was used to measure soluble Ab aggregates in brain homogenates
from mice transgenic for a human allele predisposing to Ab aggregation.
Conclusions: The proximity ligation assay is a versatile analytical technology for proteins, which can provide highly
sensitive and specific detection of Ab aggregates - and by implication other protein aggregates of relevance in
Alzheimer’s disease and other neurodegenerative disorders.
Background
In Alzheimer’s disease (AD), brain deposits of extracel-
lular amyloid-b (Ab) and intracellular tau tangles are
characteristic of the disease. Cerebrospinal fluid (CSF) is
often investigated for levels of Ab42, tau and phosho-
tau in routine diagnostics of AD [1], where decreased
Ab42 and increased tau and/or phospho-tau (Thr181P)
in CSF are indicative of the disease. These measures
are reasonably good predictors of future conversion
to AD among subjects with mild cognitive impairment,
but they are not suitable to follow disease progression
or to monitor drug intervention. Novel biomarkers are
therefore needed, and evidence suggests that soluble,
oligomeric aggregates of Ab could be such a marker.
For instance, levels of soluble forms of Ab correlate
more closely with disease severity than do the amounts
of insoluble Ab aggregates in the brain [2], and oligo-
meric Ab has been shown to be neurotoxic, lead to
synaptic dysfunction and to inhibit maintenance of hip-
pocampal long-term potentiation [3-7]. Moreover, the
so-called Arctic mutation causing early onset AD is
located within the Ab domain as are other mutations
such as the Flemish, the Dutch and the Italian muta-
tions, and this particular mutation has been shown to
specifically enhance the formation of large soluble oligo-
mers of Ab (i. e. protofibrils), suggesting the notion that
this Ab species plays a central role in disease pathogen-
esis [8,9]. We previously developed a sensitive sandwich
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both as capture and detecting antibody [10]. Using this
assay, the antibody used herein has been shown to
detect Ab protofibrils also in other, well-known, tg-mice
such as PSAPP and tg2576 [11]. Here, we demonstrate
that the proximity ligation assay (PLA) can provide even
more sensitive detection of synthetic Ab protofibrils.
PLA is an affinity-based technology enabling sensitive
and specific detection of proteins in which the detection
of proteins by sets of antibodies results in the formation
of a specific DNA sequence by ligation of two parts.
This sequence can then be amplified and quantified by
methods such as real-time, PCR [12,13]. The technique
makes use of affinity probes, typically antibodies coupled
to oligonucleotides. Upon recognition of a common tar-
g e tm o l e c u l eb yap a i ro fs u c hp r o b e s ,t h ea t t a c h e d
DNA strands are brought in proximity, allowing their
free ends to be hybridized to a connector oligonucleo-
tide that directs their joining by ligation. The reporter
DNA strand that forms upon ligation can be amplified
and quantified by methods such as real-time PCR. The
assays can be performed in the homogenous phase with
no need for washes or separations [12,13]. Alternatively,
a solid support-bound affinity reagent can be used that
offers the possibility to search for target molecules in
larger sample volumes and to remove excess probes and
undesired sample components before the ligation and
amplification steps. This approach also adds specificity
by requiring simultaneous recognition of three epitopes
on the targets [14,15]. By using a single monoclonal
antibody as the affinity reagent in all three affinity
reagents required for solid-phase PLA (SP-PLA) we
have achieved a highly sensitive assay that is specific for
Ab protofibrils, with excellent discrimination against
monomers. We demonstrate that PLA is capable of
detecting soluble Ab aggregates in brains from mice
transgenic for a pathogenic form of APP - the protein
from which Ab is derived.
Results
We have developed a solid-phase form of PLA (Figure 1)
using the mAb158 antibody for sensitive and specific
detection of Ab protofibrils, and we have compared this
assay to the previously established sandwich ELISA using
the same antibody.
The SP-PLA has been previously shown to provide a
broader dynamic range and a lower limit of detection
for a wide range of proteins compared to standard sand-
wich ELISA protein assays [14]. Using the microparticle-
based SP-PLA, Ab was first captured by monoclonal
antibodies immobilized on magnetic particles. There-
after, the Ab protofibrils were detected using a pair of
PLA probes both utilizing the same monoclonal anti-
body as the capture reagent. This form of the assay thus
ensures that only aggregates of Ab are detected. Figure
2A illustrates the detection of Ab protofibrils spiked in
buffer, and in 10% and 50% CSF. The dynamic range of
the assay on synthetic protofibrils extended over more
than six orders of magnitude, and the limit of the detec-
tion was approximately 0.1 pg/ml for Ab protofibrils
spiked in buffer, and 0.27 pg/ml for Ab protofibrils
spiked in 10% and 50% CSF. These results represent a 4
to 10-fold greater sensitivity than the mAb158 ELISA.
Figure 2B illustrates a comparison between SP-PLA and
mAb158 ELISA for detection of synthetic Ab protofi-
brils spiked in 10% CSF, where SP-PLA demonstrated a
4-fold lower limit of detection and a dynamic range four
orders of magnitude greater than that of mAb158
ELISA.
Since mAb158 also has affinity for monomeric Ab-
albeit with at least 200 times lower affinity than for pro-
tofibrils - it was of importance to examine whether the
Solid-Phase PLA
e d a f c b
Figure 1 Schematic illustration of SP-PLA. (a) Capture antibodies are immobilized on a microparticulate solid support followed by (b) capture
of target molecules from the biological sample. (c) Next, the beads are incubated with a pair of PLA probes - that is antibodies with attached
oligonucleotides - where after excess probes and other reaction components are removed by washes. (d) Next a cocktail of reagents are added
for probe ligation guided by a connector oligonucleotide, and for real-time PCR. (e) After a brief ligation step, (f) ligation products representing
detected protofibrils are detected and quantified by real-time PCR.
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assay. We therefore analyzed Ab protofibrils at a fixed
concentration of 45 pg/ml (10 pM of original monomer
concentration) in the presence of variable concentra-
tions of monomeric Ab1-16. Ab1-16 was used in order
to avoid trace amounts of Ab aggregates of the mono-
mers, and since both mAb158 and 82E1 bind this
N-terminal region of Ab [10]. As seen in Figure 3,
detection was not compromised even at a 2.2 million-
fold molar excess of Ab monomers. When the SP-PLA
was based on the monoclonal antibody, 82E1, which
recognizes a linear, conformation independent Ab epi-
tope, a lower excess of 22,000-fold Ab monomers was
needed to compromise the signal.
One of the advantages of microparticle-based SP-PLA
compared to standard ELISA and solution phase PLA
lies in the possibility of using greater volumes of the
samples. To take advantage of this opportunity we used
a modified SP-PLA protocol in which 800 μl of a sample
containing Ab protofibrils was investigated, using a cor-
respondingly higher amount of microparticles with
immobilized capture antibodies. This should be com-
pared to the 50 μls a m p l ev o l u m eu s e di nt h ec o n v e n -
tional PLA protocol. In this form of the assay we
achieved a further improved limit of detection of 0.04
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Figure 2 Detection of Ab protofibrils using SP-PLA.( A )A s s a y s
were performed in buffer (blue diamonds), in 10% CSF (red
squares), and in 50% CSF (green triangles). (B) Comparison of
SP-PLA (red squares) versus ELISA (blue diamonds) for detection of
Ab protofibrils in 10% CSF. The X-axes show concentrations of Ab
protofibrils in pg/ml and the Y-axes show cycle threshold values for
real-time PCR. In B the right Y-axis indicates the OD A450nm for
ELISA. The vertical red and blue lines indicate the limit of detection
for SP-PLA and ELISA, respectively, calculated as 2-fold standard
deviations above the background signals. Error bars indicate
standard deviations from the mean for triplicates for each reaction.
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Figure 3 SP-PLA-based detection of Ab protofibrils in the
presence of variable amounts of Ab monomers. The PLA signals
for detection of 45 pg/ml Ab protofibrils were not noticeably
affected by the presence of an up to 2.2 million-fold molar excess
of Ab monomers for the protofibril-specific mAb158-PLA (red
squares), and up to 22,000-fold molar excess of Ab monomers for
the 82E1-PLA (blue diamonds). The red and the blue circles indicate
the assay background for mAb158 and 82E1, respectively. Error bars
indicate standard deviations from the mean for triplicates for each
reaction.
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PLA protocol. Compared to the mAb158 ELISA this
assay thus detected 25-fold lower concentrations of syn-
thetic Ab protofibrils (Figure 4).
Biologically derived Ab protofibrils
The Ab protofibrils in the experiments reported so far
were all prepared by in vitro aggregation of synthetic Ab
peptides. In order to investigate the ability of the SP-PLA
to detect biologically derived soluble Ab aggregates we
used brain homogenates from five APPArc-Swe mice [16],
previously shown to have elevated levels of protofibrils
[10,11]. In a blind-test, SP-PLA revealed concentrations
of soluble Ab aggregates in brain homogenates from the
five transgenic mice, at levels ranging from 11 to 84 pg/
ml. The samples from non-transgenic mice displayed
background signals at 2 to 4 pg/ml (Figure 5A) and a
similar difference was observed using the mAb158
ELISA. We note, however, that in both transgenic mice
and controls the concentrations of protofibrils estimated
by ELISA by reference to a standard dilution series of the
in vitro aggregated form of the peptide were roughly 10-
fold higher than those recorded by SP-PLA (Figure 5B).
The differences in estimated concentrations in the two
assays could be due to the requirement for antibody
recognition of three identical determinants in SP-PLA
while two determinants are bound in the sandwich
ELISA, potentially rendering SP-PLA specific for larger
aggregates. When we used a homogenous form of PLA
where two recognition events are required to generate
detection signals [12,13] the estimated concentrations of
Ab protofibrils - and possibly other lower molecular
weight Ab species, oligomers - in the tested samples were
in the same range as those determined by ELISA (data
not shown), supporting the notion that the SP-PLA form
of the assays is limited to larger soluble Ab aggregates.
To establish the feasibility of demonstrating the presence
of Ab oligomers/protofibrils in human CSF we spiked
brain homogenates either from a transgenic or a non-
transgenic mouse in 10% human CSF. Figure 5C illustrates
successful detection of endogenous Ab aggregates from
the transgenic mouse but not from the non-transgenic
mouse after spiking the preparations in human CSF. The
results illustrate the potential of the assay to detect low
levels of Ab oligomers in human bodily fluids.
Discussion
Despite extensive efforts there remains an unmet need
for highly specific and sensitive detection of soluble
forms of the aggregated proteins that are found depos-
ited in the brain in some neurodegenerative diseases.
Sufficiently sensitive and specific methods could prove
of great value in research, drug development, and for
diagnostics and follow-up.
The proximity ligation assay has the advantage that it
can be configured to require simultaneous binding to
two or more epitopes in order to yield detectable signals.
Herein we have used SP-PLA for specific detection of
soluble Ab aggregates via recognition by three reagents
binding identical epitopes (Figure 1), thus, providing a
stringent requirement for recognition of protein aggre-
gates. This form of the assay involves one capture probe
and two PLA probes, jointly ensuring low nonspecific
background and exclusive detection of soluble aggregates
where minimally three identical epitopes of the aggre-
gated form of Ab are recognized by the antibodies.
The other salient feature of PLA - the opportunity
for DNA-based signal amplification using real-time
PCR - serves to greatly enhance detection signals from
the recognition reactions. The combination of highly
specific recognition and amplified read-out allowed
detection of protein protofibrils with increased sensi-
tivity compared to our previously established ELISA
(Figures 2B and 4). The SP-PLA allowed capture of Ab
protofibrils prior to extensive washes in a manner
similar to a sandwich ELISA to remove excess detec-
tion reagents and components of the samples that
might otherwise interfere with ligation, polymerization,
or with fluorescence detection. We used five μls a m -
ples diluted to fifty μl in reaction buffer. SP-PLA
served to further decrease background signals, provid-
ing for specific and near-linear detection of the proto-
fibrils over a broad dynamic range.
O
.
D
.
 
(
4
5
0
n
m
)
C T  average
10-1 100 101 102 103 104 10-2 0
SP-PLA
ELISA
0.05 
0.5 
5  18 
20 
22 
24 
26 
28 
30 
32 
34 
36 
38 
PLA LOD
ELISA LOD
[Aβ protofibrils] (pg/ml)
Figure 4 SP-PLA was used to detect Ab protofibrils in larger
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gates in CSF could provide a means for unambiguous,
potentially early diagnosis of AD. Other reported sensitive
assays for detection of soluble aggregate proteins such as
the bio-barcode assay rely on affinity binders specifically
recognizing the oligomeric conformations of the target
proteins [17], while in the SP-PLA-based approach the
requirement for three recognition events also contribute to
a high selectivity for protofibril conformations. A limited
study using the SP-PLA tests for detection of Ab aggre-
gates in human CSF failed to reveal signals above back-
ground for either AD patients or controls, but this does
not rule out protofibrils as a potential biomarker for the
disease. It remains possible that further improved sensitiv-
ity will be required, or the lack of signal could be due to an
inability of the antibody we used to detect the form of
aggregated Ab peptides in human CSF. Evidence has been
presented that AD patients indeed do have aggregated
forms of Ab in CSF [18,19]. The detection of endogenous
Ab aggregates spiked in human CSF (Figure 5) indicates
that SP-PLA performs adequately in this biological matrix.
Conclusions
We have established that the PLA technique provides
enhanced detection of aggregated Ab proteins, offering
high specificity, sensitivity and a wide dynamic range of
detection. This makes PLA and further improvements
thereof a promising tool for diagnostics in AD, and by
extension also in other diseases characterized by
increased levels of aggregated proteins.
Methods
Mouse brain homogenates and human CSF
Eight-month-old mice transgenic for human APPArc-Swe
(n = 5), and nontransgenic littermates (n = 5) [16] were
anesthetized with 0.4 ml Avertin (25 mg/ml) and intra-
cardially perfused with 0.9% saline solution. Frontal cor-
tex from the brains was extracted as 1:10 (tissue weight/
extraction volume ratio) in TBS (20 mmol/l Tris and
137 mmol/l NaCl, pH 7.6) with a complete protease
inhibitor cocktail (Roche Diagnostics GmbH, Man-
nheim, Germany) using a tissue grinder with teflon pes-
tle (2 × 10 strokes on ice). The homogenates were
centrifuged at 100,000 g at 4°C for 60 min to obtain a
preparation of TBS-soluble extracellular and cytosolic
proteins. The supernatant was aliquoted and stored at
-80°C prior to analysis.
CSF samples were collected by lumbar puncture at the
Memory Clinic, Uppsala University Hospital, Uppsala,
Sweden, as approved by the local ethics committee at
Uppsala University (decision number 2005:244 and Ö
48-2005). Samples were centrifuged at 1,800 × g for 10
min to eliminate cells and insoluble material, and kept
at -80°C until analysis. The CSF used in this study was
pooled from 4 healthy individuals.
Reagents
The monoclonal antibody mAb158, having selective affi-
nity for Ab in its protofibrillar conformation, has been
described previously [10]. The monoclonal antibody 82E1,
with affinity for a linear N-terminal Ab neo-epitope,
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Figure 5 Detection of endogenous Ab protofibrils using SP-PLA. Brain homogenates from five transgenic ArcSwe mice expressing elevated
levels of protofibrils and five control mice were examined using SP-PLA (A) and the mAb158 ELISA (B). The blue and red rectangles indicate the
median for control and transgenic-mice, respectively, revealing a significant difference between the two groups of mice. (C) Results of SP-PLA of
brain homogenates from transgenic and non-transgenic mice, spiked in 10% human CSF. Error bars indicate standard deviations from the mean
for triplicates for each reaction.
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Page 5 of 7was purchased from IBL International (Hamburg,
Germany). Synthetic Ab42 was purchased from American
Peptide (Sunnyvale, Ca, USA), and the Ab protofibrils
were prepared as previously described [20]. Briefly, lyophi-
lized synthetic Ab42wt was dissolved in 10 mM NaOH to
a concentration of 100 μM, and then further diluted 1:1
with 2 × PBS (50 mM phosphate buffer and 100 mM
NaCl, pH 7.4), and incubated at 37°C over night (ON) in
t h ep r e s e n c eo f5 0μM Docosahexaenoic acid (DHA) to
stabilize the protofibrils. To remove fibrillar material the
sample was centrifuged for 5 min at 17,900 × g before ana-
lyses. As determined by density gradient ultracentrifuga-
tion the mass of the Ab protofibrils in this preparation are
approximately 100-400 kDa (unpublished data). Lyophi-
lized synthetic Ab1-16wt peptide (Bachem, Bubendorf,
Switzerland) was dissolved in 10 mM NaOH, prior to use,
and diluted in 2 × PBS to a final concentration of 50 μM.
Oligonucleotide-streptavidin conjugates SLC1 (5’-
streptavidin CGCATCGCCCTTGGACTACGACTGAC-
GAACCGCTTTGCCTGACTGATCGCTAAATCGTG-3’)
and SLC2 (5’-TCGTGTCTAAAGTCCGTTACCTT-
GATTCCCCTAACCCTCTTGAAAAATTCGGCATC
GGTGA-streptavidin 3’) were purchased from Solulink
(San Diego, CA, USA), and treated prior to use with
free streptavidin to reduce the numbers of oligonucleo-
tides per streptavidin tetramer, as described [14].
The same PCR forward primer, Biofwd, 5’-CATCGC-
CCTTGGACTACGA-3’, PCR reverse primer, Biorev,
5’-GGGAATCAAGGTAACGGACTTTAG-3’,a n dc o n -
nector oligonucleotide, 5’-TACTTAGACACGACACG-
ATTTAGTTT-3’ were used in all PLA tests. These
oligonucleotides were purchased from Biomers (Ger-
many). A TaqMan probe (5’ FAM-TGACGAAC CGCT-
TTGCCTGA-MGB 3’) was obtained from Applied
Biosystems.
Solid-phase proximity ligation assay
For all PLA reactions the oligonucleotide-streptavidin
conjugates SLC1 and SLC2 were coupled to biotinylated
antibodies by incubating identical volumes of 100 nM
antibodies with 100 nM streptavidin-oligonucleotide
conjugates for 1 h at room temperature. The antibody-
oligonucleotide conjugates (PLA probes) thus obtained
were used without purification after being separately
diluted in PLA buffer (1 mM D-Biotin (Invitrogen), 0.1%
purified BSA (New England Biolabs), 0.05% Tween 20
(Sigma-Aldrich), 100 nM goat serum IgG (Sigma-
Aldrich), 0.1 μg/μl salmon sperm DNA (Invitrogen), 5
mM EDTA, 1 × PBS), and incubated for 15 min at
room temperature prior to mixing the reagents to form
a PLA probe mix.
Microparticle-based SP-PLA was carried out as
described by Darmanis et al. [14], with some modifica-
tions as follows. Briefly, capture antibodies were bound
to microparticles by using one mg of Dynabeads®
MyOne™ Streptavidin T1 microparticles (Invitrogen)
that had been washed twice with 500 μl washing buffer
(1 × PBS, 0.05% Tween 20 (Sigma-Aldrich)), using a 96-
well plate magnet (Perkin Elmer) for separation of
microparticles. The microparticles were mixed with 200
μlo f5 0n M( 1 . 5μg )o ft h es a m eb i o t i n y l a t e dm o n o c l o -
nal antibody that was used for PLA probe, and incu-
bated for 1 h at RT under rotation, followed by washes
as above. The antibody-coated microparticles were sus-
pended in 200 μl of storage buffer (1xPBS, 0.1% purified
BSA (New England Biolabs)), and stored at 4°C for up
to 2 months.
For each assay the storage buffer of one μlo fa n t i -
body-coated microparticles (≈5 μg of microparticles and
7.5 ng of antibody) was replaced by 5 μl of PLA buffer,
and the microparticles were mixed with 45 μls a m p l e s
to be investigated for Ab protofibrils. The binding reac-
tions were incubated ON at 4°C or for 1.5 h at RT
under rotation with similar efficiencies (data not
shown). The microparticles were washed twice, and 50
μl of PLA probe mix at a concentration of 30 pM for
each probe was added to each well, and incubated for
1.5 h at RT with rotation, followed by washing. Finally,
50 μl of ligation/PCR mix (1 × PCR buffer (Invitrogen),
2.5 mM MgCl2 (Invitrogen), 0.2 μM of each primer
Biofwd and Biorev, 0.4 μMT a q M a np r o b e ,0 . 0 8m M
ATP, 100 nM connector oligonucleotide, 0.2 mM
dNTPs (containing dUTP) (Fermentas), 1.5 units Plati-
num Taq polymerase (Invitrogen), 0.5 units T4 DNA
ligase (Fermentas), 0.1 units uracil-DNA glycosylase
(Fermentas)) were added, followed by a 5 min incuba-
tion at room temperature for the proximity ligation
step, before a real-time PCR was performed on an Mx-
3000 real-time PCR instrument (Stratagene), with an
initial incubation for 2 min at 95°C, and then 45 cycles
of 15 s at 95°C and 1 min at 60°C.
F o rh i g h e rv o l u m es a m p l e s ,1 0μl of antibody-coated
microparticles were transferred to a 1.5 ml tube, and
after removing the storage buffer the particles were
mixed with 0.8 ml samples to be investigated for the
presence of Ab protofibrils, and incubated ON at 4°C
with end-over-end rotation. The microparticles were
c o l l e c t e db ys p i n n i n ga t1 5 , 0 0 0r p mf o r3 0s ,a n d
washed twice. 50 μl PLA probe mix was added followed
by incubation for 1.5 h at RT. Next, the microparticles
were washed twice and transferred to optical PCR tubes,
50 μl ligation/PCR mix was added, and the real-time
PCR was performed as described above.
ELISA
The mAb158 sandwich ELISA was carried out as pre-
viously described [10]. In short, 96-well plates were
coated with 200 ng/well of mAb158 at 4°C ON before
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Page 6 of 7being blocked with 1% BSA in PBS. 100 μl samples were
added to the plate in triplicates and incubated for 2 h at
RT. 0.5 μg/ml of biotinylated mAb158 was added and
incubated for 1 h at RT, and then streptavidin-coupled
horse radish peroxidase (Mabtech, Sweden) was added
for 1 h at RT. K-blue enhanced (ANL produkter,
Sweden) was used as a peroxidase substrate and the reac-
tions were stopped with 1 M H2SO4. Wells were washed
three times between each step after blocking the plates,
and antibodies and samples were diluted in ELISA incu-
bation buffer (PBS with 0.1% BSA, 0.05% Tween-20).
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